



## Data from Lumos Pharma OraGrowth Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)

April 27, 2023

*Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowth210 Trial*

*Interim Data from OraGrowth212 Trial Highlighted in Poster Presentation*

AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](https://www.lumos-pharma.com/) (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowth210 Trial will be reviewed in an oral presentation at the 2023 Annual Meeting of the [Pediatric Endocrine Society \(PES\)](https://www.pedsoc.org/), held in San Diego, California, May 5-8, 2023. Data from the interim analysis of its OraGrowth212 Trial are also being presented as a poster during the medical meeting.

### Oral Presentation

- Title (Abstract 6178) – *Growth Response to LUM-201 in the OraGrowth210 Trial in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Interim Analysis Data (41 Subjects)*
- Lead Author – Andrew Dauber, MD, Chief of Endocrinology, Children's National Medical Center, Washington, D.C.
- Sunday, May 7, 8:15 AM – 9:15 AM local time

### Poster Presentation

- Title (Abstract 6197) – *Observed IGF-1 Serum Concentration Increase Within Normal Range After Prolonged Daily Oral LUM-201 Administration in Idiopathic Pediatric Growth Hormone Deficiency from the OraGrowth212 Trial: Interim Analysis Data*
- Lead Author – Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile
- Saturday, May 6, 12:30 PM – 2:00 PM local time: Poster presentation by David B. Karpf, MD, Chief Medical Officer, Lumos Pharma, and Adjunct Clinical Professor, Endocrinology, Stanford University School of Medicine

### About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in several Phase 2 clinical trials for the treatment of idiopathic Pediatric Growth Hormone Deficiency (iPGHD): the dose-finding OraGrowth210 Trial; the PK/PD mechanistic OraGrowth212 Trial; and a switch trial, the OraGrowth213 Trial. If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

Investor & Media Contact:

Lisa Miller  
Lumos Pharma Investor Relations  
512-792-5454  
[ir@lumos-pharma.com](mailto:ir@lumos-pharma.com)



Source: Lumos Pharma, Inc.